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Abstract
Background: Early-onset or hereditary ovarian cancer is mostly associated with BRCA1 or BRCA2 mutations. Mismatch
repair genes sequence alteration frequently cause colorectal cancer, and, in less extent, other tumors, such as ovarian
cancer. Subjects with personal and/or family history suggestive for hereditary cancer should be addressed to cancer
genetic counseling, aimed to the identification, definition and management of hereditary cancer syndrome, by a
multidisciplinary approach.
Case presentation: A woman with a very early onset epithelial ovarian cancer underwent to cancer genetic
counseling and genetic testing. Pedigree analysis suggested a clinical diagnosis of Lynch II syndrome, according to the
Amsterdam criteria. The MMRpro model showed a cumulative risk of mutation of 50.3 %, thus, genetic testing
was offered to the patient. Two germ-line mutations have been identified in exon 11 of MSH2 gene: c.1706A > T
(p.Glu569Val) and c.1711G > T (p.Glu571*). Both DNA alterations were novel mutations not yet described in literature.
The first is a missense mutation that is to be considered an unclassified variant; the second is nonsense mutation that
created a premature stop codon resulting in a truncated not functioning protein. Both genetic alterations were found
in the patients’ father DNA.
Conclusions: The present report finds out two unpublished sequence alterations in exon 11 of the MSH2 gene,
one on which can be considered causative of Lynch phenotype. Moreover, it stresses the importance of the
multidisciplinary onco-genetic counselling in order to correctly frame the hereditary syndrome, suggest the right
genetic test, and offer the most appropriate management of the cancer risk for the patients and her family members.
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Background
Progresses in the molecular genetics of cancer have led
to the identification of genes predisposing for hereditary
ovarian cancer [1]. About 84 % of hereditary ovarian
cancers derive from BRCA1 or BRCA2 mutations that
sustain the hereditary breast/ovarian cancer (HBOC)
syndrome. The overall risk of developing ovarian cancer
is about 49 % for BRCA1 and 11 % for BRCA2 mutated
subjects, and the mean age at diagnosis is 50.8 years [2].
Few cases (about 2 %) of hereditary ovarian cancer de-
rive from mutation in mismatch repair (MMR) genes
that sustain the Lynch syndrome [3]. Carriers of MLH1/
MSH2 or MSH6 genes mutations have an overall risk of
developing ovarian cancer of about 4–24 and 1–11 %,
respectively. The mean age at diagnosis of ovarian can-
cer for these patients is 42 and 46 years, respectively.
So far, numerous sequence variants listed in the inter-
national database [4] have been identified in MMR genes
(MLH1, MSH2, MSH6, PMS2, MSH3). The majority of
mutations in the MMR genes identified are missense,
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nonsense or small insertions/deletions. Moreover, large
genomic rearrangements can predispose to Lynch syn-
drome [5].
Given the complexity of issues related to hereditary/fa-
milial cancers and clinical implications of genetic testing,
cancer genetic counseling actually is the most suitable
approach to manage high risk subjects. There is general
consensus that the management of hereditary and famil-
ial cancer requires a multidisciplinary approach [6, 7].
The counseling model used at our Clinical Unit foresees
close links with the oncologist, psychologist, geneticist
and other professionals [8].
Here we report a case in which mutational analysis
was performed, within cancer genetic counseling, and
revealed two novel sequence variants in the MSH2 gene,
not listed in the SNP database.
Methods
Cancer genetic counseling
Patients or disease-free subjects with a suspected famil-
iar or hereditary tumors are referred to the Hereditary
and Familiar Tumor Unit at the Department of Clinical
Medicine of the University Hospital Federico II in
Naples. Cancer genetic counseling is performed by a
multidisciplinary team including dedicated oncologist
and psychologist, according to the multistep model de-
signed and validated within the Italian Network for
“Hereditary Breast and/or Ovarian Cancer”. Structured
sessions with a psycho-oncologist for psychological as-
sessment, psychological counseling interventions and
psychotherapy or emotional support are also planned for
patients and their at-risk subjects [6, 9]. During the
cancer genetic counseling steps devoted to information-
giving and pedigree construction, anxiety and depression
levels were assessed from replies to self-report question-
naire administered by the psycho-oncologist. The
Hospital and Depression Scale (HAD Scale) were used
during psychological interview to determine the pres-
ence or not of distress [10].
The hereditary risk is calculated according by clinical
and probabilistic tools, such as the Amsterdam and/or
Bethesda criteria and MMRpro model. When clinical
criteria are satisfied and/or an a priori hereditary risk is
≥10 %, the genetic testing for the MMR genes is offered
to the affected subjects [11, 12]. Preventive measures are
offered on the basis of risk profile and genetic test
results according with NCCN guidelines.
Written informed consent was obtained for publication
of this case.
Mutational analysis
Total genomic DNA was extracted from 4 mL peripheral
blood lymphocytes of the patient and her parents using
a BACC2 Nucleon Kit (GE Healthcare). All MLH1, and
MSH2 exons were amplified, including intron-exon
boundaries, using customized primer sets. A Transge-
nomic Wave DNA Fragment Analysis System (3500 HT,
Transgenomic Inc., Omaha, Nebraska, USA) was used
to perform denaturing High Performance Liquid Chro-
matography (dHPLC) analysis. Abnormal elution profiles
were identified by visual inspection of the chromatogram
on the basis of the appearance of one or more additional
earlier eluting peaks. For abnormal dHPLC profiles,
genomic DNA of the patient was re-amplified and se-
quenced in both the forward and reverse directions
using an ABI 3100 Genetic Analyser (Applied Biosystems,
Foster City, Ca., USA).
Total RNA was extracted from the lymphocytes of the
patient and three normal controls by using Trizol re-
agent (Invitrogen, Life Technologies, Ca, USA). A total
of 1 microgram of RNA from each sample was retro-
transcribed. cDNA was synthesized using 1 μg of total
RNA, 500 ng of random hexamers and 1 μl Superscript
III reverse transcriptase (Invitrogen, Life Technologies,
Ca, USA), in the presence of 4 μl 5X RT buffer, 1 μl
DTT (0.1 M) and 1 mM dNTPs. The reaction was run
for 50 min at 42 °C in a 20 μl reaction volume, heated to
70 °C for 15 min and quick chilled on ice.
For MSH2 analysis, cDNA was amplified using the for-
ward primer overlapping the junction between exons 9–10
(5′-CCAGAGATCTTGGCTTGGAC-3′) and the reverse
primer located in exon 15 (5′-AGCACTTCTTTGCT
GCTGGT-3′). The amplified fragment was visualized on
an 8 % polyacrilamide gel. Anomalous bands were excised
from the gel and re-suspended in H2O. The bands were
then re-amplified using the same forward primer and
a reverse primer in exon 13 (5′-CTCACATGGCA-
CAAAACACC-3′); subsequently, these fragments were
sequenced.
Microsatellite instability assay
Microsatellite instability (MSI) was tested on paired sam-
ples from peripheral blood lymphocytes and paraffin-
embedded tumor ovarian tissues. The MSI status was
evaluated with a fluorescent multiplex system comprising
6 mononucleotide repeats (BAT-40, BAT-25, BAT-26, NR-
21, NR-24 and NR-27), 4 dinucleotide repeats (D2S123,
D5S346, D18S58 and D17S250) and 2 tetranucleotide re-
peats (TPOX and THO1) as biochemical markers of indi-
viduality using the CC-MSI Kit (AbAnalitica, Padova,
Italy) and subsequent capillary electrophoresis analysis
using an ABI 3130 Prism (Applied Biosystems). Tumors
were classified as “highly unstable” (MSI-H), if ≥ 30 % of
the markers showed instabilities and as “low unstable”
(MSI-L), if ≥ 10 % of the markers showed instabilities; if
no allele difference between DNA extracted by normal
and tumoral tissues was observed, tumors were classified
as microsatellite-stable (MSS).
Pensabene et al. Hereditary Cancer in Clinical Practice  (2016) 14:18 Page 2 of 7
Immunohistochemistry analysis
The expression levels of MSH2, MLH1 and MSH6 pro-
teins were measured by immunohistochemical (IHC)
analysis on paraffin-embedded tissue sections of ovarian
cancer from our patient. The IHC analysis was per-
formed on a Benchmark XT automatized immunostainer
(Ventana Medical Biosystems, Tucson, USA). The anti-
body used were anti-MSH6, mouse monoclonal clone
44, anti-MSH2, mouse monoclonal clone G219-1129,
and anti-MLH1, mouse monoclonal clone M1 (Ventana).
The detection system used was an iVIEW DAB Detection
Kit (Ventana) which is based on the Streptavidin-Biotin-
conjugated revelation system. Nuclear staining was
observed with an optical microscope with positivity repre-
sented by the presence of brown staining. This positivity
was compared to blue nuclear epitopes, in which the spe-
cific antigen was not present. The internal positive control
was represented by lymphocytes, stroma and functional
mucosal crypts, while the negative control was obtained
by slides without primary antibody. Nuclear immunoreac-
tivity scores were assigned using range from 0 to 100 %.
Case presentation
A 29-year-old woman received diagnosis of clear cell
ovarian adenocarcinoma, stage IA according to the
International Federation of Gynecology and Obstetrics
classification, and underwent radical surgery, followed
by six cycles of carboplatin and paclitaxel. She requested
counseling because of a very early-onset ovarian carcin-
oma and a familial clustering of colon cancer both on
maternal and paternal lines.
Pedigree analysis revealed one case of colon cancer
and one of uterine cancer on paternal line, and four
colon cancers, one endometrial cancer, and one both
colon and endometrial cancer on maternal line (Fig. 1).
Clinical diagnosis of Lynch II syndrome was done ac-
cording to the Amsterdam criteria [12]. The MMRpro
[11] model showed a cumulative risk of mutation of
50.3 % (22 % for hMLH1, 24.3 % for hMSH2, and 6.6 %
for hMSH6), thus, genetic testing was offered to the
patient.
Mutation detection was performed on MLH1 and
MSH2 coding regions of the index case and her parents.
The patient was found to be heterozygous for two se-
quence alterations (c.1706A > T and c.1711G > T), both
in exon 11 of MSH2 gene. The first mutation predicted
a substitution of a glutamate residue with a valine resi-
due at position 569 (p.Glu569Val); the second mutation
created a premature stop of codon transcription, result-
ing in a truncated protein (p.Glu571*). Both are novel
genetic variants not yet described in literature.
Direct sequencing of MSH2 mRNA transcript includ-
ing exon 9–15 revealed the presence of only the wild
type allele (Fig. 2). Moreover, electrophoresis of this
transcript showed an abnormal fragment, suggestive of
an aberrant splicing event. Direct sequencing of this ab-
errantly spliced transcript revealed the loss in frame of
the entire exon 11; this transcript fragment resulted in a
new exon connection between 10 and 12 exons (Fig. 3).
The same two genetic alterations were found in the
patients’ father DNA.
Genetic testing performed on DNA from patient’s
mother revealed a pathogenic mutation, c.229 T > C, in
exon 3 of the MLH1 gene, which determines a dramatic
amino-acid change at protein level, p.Cys77Arg. This
mutation was not identified in our index case.
BRCA1 and BRCA2 genes were also analysed, and no
mutation was found.
Instability in three microsatellite markers (BAT40,
D18S58 and D2S123) out of ten was found thus, ovarian
cancer tissue from our proband showed a MSI-H status.
The IHC analysis revealed loss of expression of
MSH2/MSH6 protein complex on the tissue sections of





















Fig. 1 Patient’s pedigree. The arrow indicates the early-onset ovarian cancer proband. Filled symbols indicate subjects affected by cancer; square =male;
circle = female. The numbers after cancer sites indicate the age at diagnosis. The age of death is reported if known. Abbreviations: D = deceased
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In post-test counseling, the patient was informed
about the results of the genetic test and their clinical im-
plications. A surveillance program was proposed, includ-
ing yearly colonoscopy and urinary cytology, according
with NCCN guidelines for MSH2 gene mutation carriers,
and breast ultrasound and magnetic resonance, because
of her young age, and complex breast parenchyma.
The HAD Scale revealed moderate levels of anxiety
and depression, and the psychological interview showed
a significant concern for the hereditary risk and an ex-
perience of suffering for the foreclosure of motherhood
because of bilateral oophorectomy. Cancer genetic coun-
selling had a positive impact on perception of control
over important life events, such as experience of cancer
disease and physical and psychic sequelae. It promoted
also a positive reappraisal of chances and goals. At the
conclusion of counseling, indeed, the patient has ad-
hered to the intensified surveillance program, and chose
to consider the possibility of an adoption path for a child
with her husband.
Discussion
Cancer genetic counseling should be always offered during
the work-up of young patients with epithelial ovarian can-
cer, in order to screen the presence of a hereditary syn-
drome and to improve the oncological follow-up including
intensified surveillance. Clinicians should be particularly
careful to the evaluation of a positive family history of can-
cer, being ovarian cancer involved in three different syn-
dromes, such as site-specific, HBOC and Lynch Syndrome.
The proper placement of the present case within
Lynch syndrome frame has been very helpful to direct
appropriately the genetic testing, and the surveillance
planning. In fact, MSH2 gene mutation carriers are
known to have an increased risk for cancer in different
body sites, such as colon, breast and genitourinary tract.
b
a
Fig. 2 The heterozygous state for the mutations (c.1706A > T) and (c.1711G > T) at exon 11 of MSH2 gene. a MSH2 genomic sequence analysis
(fragment including exon 11) showing the two mutations identified in our index case. The arrow indicates the position of two mutations. b MSH2 cDNA
sequence analysis (fragment including exons 9–15) showing the two mutations at mRNA level. The arrow indicates the lowering peak of mutant allele
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Genetic testing of our patient’s DNA showed two se-
quence alterations in exon 11 of the MSH2 gene. So far,
both the missense (c.1706A > T) and the nonsense
(c.1711G > T) mutations are not described in literature.
Parental testing revealed that both mutations were of
paternal origin, and they were on the same allele. The
nonsense mutation determines a premature stop codon
(p.Glu571*), therefore, it has a clear functional role, be-
cause it creates a truncated protein, thus, it can be con-
sidered causative of Lynch phenotype. The missense
mutation (c.1706A > T) should result in an amino acid
change at the protein level (p.Glu569Val). A large num-
ber of genetic alterations that are still classified as “vari-
ants of unknown significance” have pathogenic effects
on the mRNA splicing process [13]. In the present case,
the missense mutation could activate a cryptic splicing
site. Indeed, the electrophoresis of MSH2 cDNA ampli-
fied fragment showed an abnormal band which was
found to correspond to an aberrantly spliced transcript,
with the loss of exon 11. This transcript showed a new
junction between exons 10–12, and it should create a
premature stop codon in exon 12 (9 codons next the
new junction). Interestingly, MSH2 cDNA sequencing
analysis showed a dramatic reduction of the signal corre-
sponding to the mutated transcript with respect to the
wild type allele. Therefore, it is conceivable that a
nonsense-mediated decay (NMD) mechanism [14] of
transcripts bearing the nonsense c.1711G > T mutation
a
SM        1 2
b
Fig. 3 Characterization of aberrant splicing fragment. a 8 % polyacrilamide gel electrophoresis of MSH2 cDNA RT-PCR analysis of fragment in a
normal control (1) and in the index case (2). SM size marker XIV Roche. The arrow indicates the abnormal band lower than the wild type band
(1172 bp) of about 1000 bp. b MSH2 cDNA sequence analysis of abnormal band showing the skipping of exon 11. The arrow indicates the frameshift
(between 11 and 12 exons) due to contamination with wild type allele
Fig. 4 MSH2, MSH6 and MLH1 immunohistochemistry (IHC) results in the ovary tumor section of patient carrier of c.1706A > T and c.1711G > T
variants in MSH2 exon 11. a Absence of MSH2 protein in the tumor cells; b weak presence of MSH6 protein in the tumor cells; c normal IHC for
MLH1 protein in the tumor cells. Filled arrow heads point to IHC– tumor cells, open arrows heads point to IHC+ tumor cells. Blue nuclear staining
of lymphocytes indicates positive internal control
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or, alternatively, transcripts missing exon 11 due to the
c.1706A > T missense mutation is responsible for the re-
duced levels of the mutated allele. To our best of know-
ledge this is the first report of co-existence of two
putative functional mutations on a single MSH2 allele;
both these variants create truncated transcripts that are
prematurely degraded. Although, we can not speculate
that these two variants have a synergistic effect on Lynch
phenotype, we can likely conclude that these mutations
in MSH2 gene are responsible of proband’s phenotype.
Indeed, IHC data showed the loss expression of MSH2
and MSH6 proteins on ovarian cancer tissue from our
index case and the somatic DNA extracted from this tis-
sue also showed a status MSI-H; it was compatible with
genotype of our proband.
Finally, the index case was not carrier of mutation in
MLH1 gene identified in her mother. The early onset of
ovarian cancer, that is an infrequent tumor in Lynch
syndrome, could rather be explained by the presence of
modifier genes of phenotype [15].
Hereditary ovarian cancer involves a complex array of
medical and psychological aspects that impact on af-
fected subjects and their family members. The anxiety
and depression levels showed by the patient were in rela-
tion to the threat of hereditary cancer risk and the se-
quelae of oncological treatments [16]. The present case
confirms that cancer genetic counselling is a successful
modality in the management of at-risk subjects by a
multidisciplinary team, including psycho-oncologist. The
space of emotional containment offered by the cancer
genetic counselling has provided a sense of safety for the
patient to explore feelings that were experienced as over-
whelming and confusing.
Conclusions
The identification of novel mutations with a clear patho-
genic effect is a very important finding, because it allows
to understand better the onset of cancers in very young
subjects, to offer the most appropriate cancer genetic
counselling and cancer risk management to the patient
and her family members.
The present report also emphasizes that the multidiscip-
linary approach is the most appropriate way to take care
of a young patient with ovarian cancer, in order to manage
the complex issues related to ovarian cancer diagnosis,
long-term sequelae and genetic predisposition to cancer.
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